Brokerages Expect Travere Therapeutics, Inc. (NASDAQ:TVTX) Will Post Quarterly Sales of $53.17 Million

Brokerages expect Travere Therapeutics, Inc. (NASDAQ:TVTXGet Rating) to post sales of $53.17 million for the current quarter, according to Zacks. Five analysts have issued estimates for Travere Therapeutics’ earnings, with the highest sales estimate coming in at $55.13 million and the lowest estimate coming in at $49.30 million. Travere Therapeutics reported sales of $47.41 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.1%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Travere Therapeutics will report full-year sales of $213.92 million for the current year, with estimates ranging from $200.58 million to $229.02 million. For the next year, analysts expect that the firm will report sales of $278.83 million, with estimates ranging from $234.00 million to $345.76 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Travere Therapeutics.

Travere Therapeutics (NASDAQ:TVTXGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.12). Travere Therapeutics had a negative return on equity of 55.22% and a negative net margin of 79.16%. The firm had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.40 million. During the same period in the prior year, the company posted ($2.37) EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year.

Several research analysts have issued reports on TVTX shares. Piper Sandler started coverage on Travere Therapeutics in a report on Wednesday, March 30th. They set an “overweight” rating and a $42.00 price objective on the stock. Zacks Investment Research cut shares of Travere Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, HC Wainwright began coverage on shares of Travere Therapeutics in a research report on Monday, February 28th. They set a “buy” rating and a $45.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Travere Therapeutics has an average rating of “Buy” and an average price target of $34.11.

In other Travere Therapeutics news, CEO Eric M. Dube sold 7,873 shares of the stock in a transaction dated Monday, January 24th. The stock was sold at an average price of $24.98, for a total transaction of $196,667.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric M. Dube sold 4,813 shares of the stock in a transaction dated Monday, January 31st. The stock was sold at an average price of $27.40, for a total value of $131,876.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,069 shares of company stock valued at $572,764. 4.31% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. CM Management LLC increased its holdings in Travere Therapeutics by 33.3% during the 3rd quarter. CM Management LLC now owns 80,000 shares of the company’s stock worth $1,940,000 after purchasing an additional 20,000 shares in the last quarter. Laurion Capital Management LP boosted its stake in shares of Travere Therapeutics by 33.8% during the 3rd quarter. Laurion Capital Management LP now owns 758,951 shares of the company’s stock worth $18,404,000 after buying an additional 191,768 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Travere Therapeutics by 246.4% during the 3rd quarter. SG Americas Securities LLC now owns 50,197 shares of the company’s stock worth $1,217,000 after buying an additional 35,705 shares during the last quarter. Public Sector Pension Investment Board boosted its stake in shares of Travere Therapeutics by 81.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 238,000 shares of the company’s stock worth $5,772,000 after buying an additional 107,000 shares during the last quarter. Finally, International Biotechnology Trust PLC boosted its stake in shares of Travere Therapeutics by 1,800.0% during the 3rd quarter. International Biotechnology Trust PLC now owns 380,000 shares of the company’s stock worth $9,215,000 after buying an additional 360,000 shares during the last quarter.

NASDAQ:TVTX opened at $28.24 on Friday. The stock’s fifty day moving average price is $26.90 and its two-hundred day moving average price is $27.61. Travere Therapeutics has a 52-week low of $12.75 and a 52-week high of $31.65. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.64 and a current ratio of 4.70. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -9.32 and a beta of 0.74.

Travere Therapeutics Company Profile (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Recommended Stories

Get a free copy of the Zacks research report on Travere Therapeutics (TVTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.